202TiP ASTEFANIA: A phase III study of trastuzumab emtansine (T-DM1) plus atezolizumab or placebo as adjuvant therapy in patients with residual invasive breast cancer after neoadjuvant HER2-targeted therapy and chemotherapy
| Autor: | Schmid, P., Bachelot, T., Bianchini, G., Harbeck, N., Loi, S., Park, Y.H., Prat, A., Gilham, L., Boulet, T., Gochitashvili, N., Monturus, E., Lambertini, C., Nyawira, B., Knott, A., Hurvitz, S.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S445-S446 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|